Ask AI
ProCE Banner Events

Share

The Evolving Understanding of IgA Nephropathy: Implications of New Treatment for Managed Care Pharmacy Professionals

Join expert faculty to discuss IgA nephropathy, pathophysiology, new and emerging therapies, and methods to address economic and disease burden in the managed care setting. Register today! In this live symposium, expert faculty will discuss IgA nephropathy, pathophysiology, new and emerging therapies, and methods to address economic and disease burden in the managed care setting. Register today!

Join us from 6:00 PM – 6:30 PM Eastern Time (ET) for in-person registration or at 6:30 PM ET online when the symposium begins. 



Pharmacists: 1.50 contact hours (0.15 CEUs)

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for managed care pharmacists and specialty and clinical pharmacists who care for patients with IgAN, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Time and location

Tuesday, October 17, 2023

6:00 PM - 8:00 PM Eastern Time (ET)

In-personVirtual

Orlando World Center Marriott
8701 World Center Drive
Orlando, Florida 32821

Canary 3 & 4

Agenda

In-person Registration: 6:00 PM – 6:30 PM Eastern Time (ET)

Presentation: 6:30 - 8:00 PM Eastern Time (ET)

  • Welcome and Baseline Polling
  • Progression Risk of IgA Nephropathy
  • Latest Clinical Evidence for the Management of IgA Nephropathy
  • New and Emerging Therapies for IgA Nephropathy
  • Managed Care Strategies to Impact Economic and Disease Burden of IgA Nephropathy
  • Question and Answer Session

Location

Venue Name

Orlando World Center Marriott

Address

Orlando World Center Marriott
8701 World Center Drive
Orlando, Florida 32821

Room Name

Canary 3 & 4

CME/CE Info

Program Overview
The primary purpose of this program is to arm healthcare professionals with the tools to address the economic impact of IgA nephropathy by providing a thorough overview of disease prevalence, new and emerging treatment options, and discussing strategies for optimizing patient outcomes, medication access, and healthcare delivery.

Goal Statement
The goal of this program is to improve the knowledge and competence of pharmacist learners about new and emerging therapies for IgAN.

Target Audience
This program is intended for managed care pharmacists and specialty and clinical pharmacists who care for patients with IgAN, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

Learning Objectives

  • Describe the current understanding of the pathogenesis and pathophysiology of IgA nephropathy in alignment with available and potential treatment targets
  • Analyze the pharmacology and clinical outcomes data for recently FDA-approved and emerging therapies to facilitate optimal integration into treatment algorithms/clinical pathways
  • Examine the economic and clinical burden of IgAN and opportunities for managed care interventions to improve costs and patient outcomes

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-027-L01-P has been assigned to this live application-based activity (initial release date 10/17/2023). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC

Supported by an educational grant from Calliditas Therapeutics.

Contact Information

Contact ProCE

For customer support please click here.

Mailing Address:

 

ProCE, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.